期刊文献+

Autologous bone marrow stem cell transplantation for the treatment of type 2 diabetes mellitus 被引量:10

Autologous bone marrow stem cell transplantation for the treatment of type 2 diabetes mellitus
原文传递
导出
摘要 Background Autologous peripheral stem cell transplantation was first reported in 2007 to treat type 1 diabetes mellitus (DM) and achieved encouraging effect, but whether similar outcome can be achieved in type 2 DM is not well demonstrated. The objective of this study was to determine the effect of combination of autologous bone marrow stem cell transplantation (BMT) and hyperbaric oxygen treatment on type 2 DM. Methods The study involved 31 patients with type 2 DM (aged 33 to 62 years) from January 2009 to January 2011 in the Central Hospital of Wuhan, China. Clinical variables (body mass index, duration of DM, insulin requirement, oral hypoglycemic drugs, time free from insulin, time free from oral drugs) and laboratory variables (hemoglobin Alc (HbAlc)) mononuclear cells infused, and C-peptide in four time points) were assessed. Purified bone marrow stem cells were infused into major pancreatic arteries. Follow-up was performed at the 30, 90, 180, 360, 540 and 720 days (mean 321 days) after BMT. Results Mean HbAlc values showed a significant reduction during follow-up in all patients after BMT. It decreased by more than 1.5% (from 8.7% to 7.1%) as quickly as at 30 days after BMT. Afterwards mean HbAlc fluctuated between plus or minus 0.5% until 24 months rather than declined continuously. At 90 days after the combined therapy C-peptide increased significahtly compared with baseline (P 〈0.0001). But in other time points C-peptide was similar with baseline data (P〉0.3). All patients had insulin and/or oral hypoglycemic drugs reduced to different levels. The dose of insulin of 7 patients (7/26, 27%) reduced for a period of time after BMT. Conclusions Combined therapy of intrapancreatic BMT and hyperbaric oxygen treatment can improve glucose control and reduce the dose of insulin and/or oral hypoglycemic drugs in type 2 DM patients, but it only improve pancreatic 13-cell function transiently. Further randomized controlled clinical trials involved more patients will be required to confirm these findings and the mechanism needs to be illustrated deeply. Background Autologous peripheral stem cell transplantation was first reported in 2007 to treat type 1 diabetes mellitus (DM) and achieved encouraging effect, but whether similar outcome can be achieved in type 2 DM is not well demonstrated. The objective of this study was to determine the effect of combination of autologous bone marrow stem cell transplantation (BMT) and hyperbaric oxygen treatment on type 2 DM. Methods The study involved 31 patients with type 2 DM (aged 33 to 62 years) from January 2009 to January 2011 in the Central Hospital of Wuhan, China. Clinical variables (body mass index, duration of DM, insulin requirement, oral hypoglycemic drugs, time free from insulin, time free from oral drugs) and laboratory variables (hemoglobin Alc (HbAlc)) mononuclear cells infused, and C-peptide in four time points) were assessed. Purified bone marrow stem cells were infused into major pancreatic arteries. Follow-up was performed at the 30, 90, 180, 360, 540 and 720 days (mean 321 days) after BMT. Results Mean HbAlc values showed a significant reduction during follow-up in all patients after BMT. It decreased by more than 1.5% (from 8.7% to 7.1%) as quickly as at 30 days after BMT. Afterwards mean HbAlc fluctuated between plus or minus 0.5% until 24 months rather than declined continuously. At 90 days after the combined therapy C-peptide increased significahtly compared with baseline (P 〈0.0001). But in other time points C-peptide was similar with baseline data (P〉0.3). All patients had insulin and/or oral hypoglycemic drugs reduced to different levels. The dose of insulin of 7 patients (7/26, 27%) reduced for a period of time after BMT. Conclusions Combined therapy of intrapancreatic BMT and hyperbaric oxygen treatment can improve glucose control and reduce the dose of insulin and/or oral hypoglycemic drugs in type 2 DM patients, but it only improve pancreatic 13-cell function transiently. Further randomized controlled clinical trials involved more patients will be required to confirm these findings and the mechanism needs to be illustrated deeply.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第22期3622-3628,共7页 中华医学杂志(英文版)
关键词 bone marrow stem cells TRANSPLANTATION hyperbaric oxygen therapy diabetes mellitus bone marrow stem cells transplantation hyperbaric oxygen therapy diabetes mellitus
  • 相关文献

参考文献1

二级参考文献10

  • 1UK Prospective Diabetes Study Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[].The Lancet.1998
  • 2Shapiro AM,,Lakey JR,Ryan EA,Korbutt GS,Toth E,Warnock GL, et al.Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen[].The New England Journal of Medicine.2000
  • 3Gunnarsson R,Klintmalm G,Lundgren G,Wilczek H,Ostman J,Groth CG.Deterioration in glucose metabolism in pancreatic transplant recipients given cyclosporine[].The Lancet.1983
  • 4Assady S,Maor G,Amit M,Itskovitz-Eldor J,Skorecki KL,Tzukerman M.Insulin production by human embryonic stem cells[].Diabetes.2001
  • 5Yang L,Li S,Hatch H,Ahrens K,Cornelius JG,Petersen BE.Peck AB: In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine homone-producing cells[].Proceedings of the National Academy of Sciences of the United States of America.2002
  • 6Bonner-Weir S,Taneja M,Weir GC,Tatarkiewicz K,Song KH,Sharma A,et al.In vitro cultivation of human islets from expanded ductal tissue[].Proceedings of the National Academy of Sciences of the United States of America.2000
  • 7Ramiya VK,Maraist M,Arfors KE,Schatz DA,Peck AB,Cornelius JG.Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells[].Nature Medicine.2000
  • 8Timper K,Seboek D,Eberhardt M,Linscheid P,Christ-Crain M,Keller U,Müller B,Zulewski H.Human adipose tissue-derived mesenchymal stem cells differenti- ate into insulin,somatostatin,and glucagon expressing cells[].Biochemical and Biophysical Research Communica- tions.2006
  • 9Pittenger MF,Mackay AM,Beck SC,Jaiswal RK,Douglas R,Mosca JD et al.Multilineage potential of adult human mesenchymal stem cells[].Science.1999
  • 10Krause,DS,Theise,ND,Collector,MI,Henegariu,O,Hwang,S,Gardner,R,Neutzel,S,Sharkis,SJ.Multi-organ, mutli-lineage engraftment by a single bone marrow[].derived stem cell Cell.2001

共引文献56

同被引文献54

引证文献10

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部